Arrest of chronic acid suppressant drug use after successful Helicobacter pylori eradication in patients with peptic ulcer disease:: a six-month follow-up study

被引:19
作者
Hurenkamp, GJB
Grundmeijer, HGLM
Van der Ende, A
Tytgat, GNJ
Assendelft, WJJ
Van der Hulst, RWM
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Gen Practice, Div Publ Hlth, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol, NL-1105 AZ Amsterdam, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Dept Med Microbiol, NL-1105 AZ Amsterdam, Netherlands
[4] Kennemer Gasthuis, Dept Gastroenterol, Haarlem, Netherlands
关键词
D O I
10.1046/j.1365-2036.2001.01017.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: It remains controversial whether successful H. pylori eradication leads to relief of dyspepsia and the subsequent arrest or tapering of acid-suppressant drug therapy, or to an aggravation of acid-related dyspepsia requiring more acid-suppressant drug intake. Aim: To evaluate prospectively the effect of H. pylori eradication on the requirement of acid-suppressant drug or antacids and the evolution of dyspeptic symptoms in chronic acid-suppressant drug users with peptic ulcer disease. Materials and methods: The use of acid-suppressant drugs, rescue antacids and predominant symptoms were recorded prospectively during 24 weeks after H. pylori eradication therapy in 75 peptic ulcer disease patients. Results: In 71 patients with complete follow-up, ulcers were healed at follow-up endoscopy and H. pylori was successfully eradicated. After 6 months, 93% (66 out of 71) of chronic acid-suppressant drug users had stopped acid-suppressant drug intake. The mean daily acid-suppressant drug dosage per patient decreased from 1.72 at entry to 0.03 units acid-suppressant drug (98%; P < 0.0001) during follow-up. The mean number of antacid tablets/day/patient was 0.26 during follow-up for the relief of mild inter-current dyspeptic symptoms. Medication use was not different in peptic ulcer disease patients with or without gastrooesophageal reflux disease at baseline, The prevalence of gastro-oesophageal reflux disease decreased from 42% before to 35% after H. pylori eradication (N.S.). Conclusion: Successful H. pylori eradication in peptic ulcer disease patients almost completely eliminates the need for acid-suppressant drug regardless of the presence or absence of gastro-oesophageal reflux disease at entry.
引用
收藏
页码:1047 / 1054
页数:8
相关论文
共 18 条
[1]  
Boyd EJS, 1996, AM J GASTROENTEROL, V91, P1539
[2]  
ElOmar E, 1996, AM J GASTROENTEROL, V91, P355
[3]  
FULLARTON GM, 1998, GUT, V42, P159
[4]   Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status [J].
Gillen, D ;
Wirz, AA ;
Ardill, JE ;
McColl, KEL .
GASTROENTEROLOGY, 1999, 116 (02) :239-247
[5]   Repeat prescribing of ulcer healing drugs in general practice - Prevalence and underlying diagnosis [J].
Goudie, BM ;
McKenzie, PE ;
Cipriano, J ;
Griffin, EM ;
Murray, FE .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1996, 10 (02) :147-150
[6]  
Hurenkamp G J, 1999, Ned Tijdschr Geneeskd, V143, P410
[7]   Equally high efficacy of 4, 7 and 10-day triple therapies to eradicate Helicobacter pylori infection in patients with ulcer disease [J].
Hurenkamp, GJB ;
van der Ende, A ;
Grundmeijer, HGLM ;
Tytgat, GNJ ;
Van der Hulst, RWM .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2000, 14 (08) :1065-1070
[8]   Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis [J].
Labenz, J ;
Blum, AL ;
Bayerdorffer, E ;
Meining, A ;
Stolte, M ;
Borsch, G .
GASTROENTEROLOGY, 1997, 112 (05) :1442-1447
[9]  
Malfertheiner P, 1997, GUT, V41, P8
[10]  
McColl KEL, 2000, AM J GASTROENTEROL, V95, P101